EQUITY ALERT: ROSEN, NATIONAL INVESTOR COUNSEL, Announces Investigation of Securities Claims Against LogicBio Therapeutics, Inc. – LOGC

NEW YORK--(BUSINESS WIRE)--Rosen Law Firm, a global investor rights law firm, announces it is investigating potential securities claims on behalf of shareholders of LogicBio Therapeutics, Inc. (NASDAQ: LOGC) resulting from allegations that LogicBio may have issued materially misleading business information to the investing public.

On February 10, 2020, post-market, LogicBio issued a press release announcing “the U.S. Food and Drug Administration (FDA) has placed a clinical hold on [LogicBio’s] Investigational New Drug (IND) submission for LB-001 for the treatment of methylmalonic acidemia (MMA) pending the resolution of certain clinical and nonclinical questions.”

On this news, LogicBio’s share price fell sharply during intraday trading on February 11, 2020, on unusually high trading volume.

Rosen Law Firm is preparing a class action lawsuit to recover losses suffered by LogicBio investors. If you purchased shares of LogicBio please visit the firm’s website at http://www.rosenlegal.com/cases-register-1776.html to join the class action. You may also contact Phillip Kim of Rosen Law Firm toll free at 866-767-3653 or via email at [e-mail] or [e-mail].

Follow us for updates on LinkedIn: https://www.linkedin.com/company/the-rosen-law-firm or on Twitter: https://twitter.com/rosen_firm or on Facebook: https://www.facebook.com/rosenlawfirm.

Rosen Law Firm represents investors throughout the globe, concentrating its practice in securities class actions and shareholder derivative litigation. Rosen Law Firm was Ranked No. 1 by ISS Securities Class Action Services for number of securities class action settlements in 2017. The firm has been ranked in the top 3 each year since 2013. Rosen Law Firm has secured hundreds of millions of dollars for investors.

Attorney Advertising. Prior results do not guarantee a similar outcome.